Drugs / Temelimab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01699555 | Jul 2011 → Mar 2012 | multiple sclerosis | GeNeuro Innovation SAS | Completed | No outcome recorded |
| Phase 27 trials · 2 missed | ||||||
| Phase 2 | NCT05497089 | Aug 2022 → May 2024 | post-COVID-19 disorder | GeNeuro SA | Completed | Missed primary |
| Phase 2 | NCT05049161 | Aug 2021 → May 2022 | multiple sclerosis | GeNeuro Innovation SAS | Terminated | No outcome recorded |
| Phase 2 | NCT04480307 | Jun 2020 → Jan 2022 | multiple sclerosis | GeNeuro Innovation SAS | Completed | No outcome recorded |
| Phase 2 | NCT03179423 | Jun 2017 → Sep 2018 | type 1 diabetes mellitus | GeNeuro SA | Completed | No outcome recorded |
| Phase 2 | NCT03239860 | Jun 2017 → Nov 2018 | relapsing-remitting multiple sclerosis | GeNeuro SA | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02782858 | Apr 2016 → Aug 2017 | relapsing-remitting multiple sclerosis | GeNeuro SA | Completed | Missed primary |
| Phase 2 | NCT01639300 | Jul 2012 → Apr 2014 | multiple sclerosis | GeNeuro Innovation SAS | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03574428 Comparator | May → Nov 2018 | multiple sclerosis | GeNeuro SA | Completed | No outcome recorded |
| Phase 1 | NCT02452996 Comparator | Apr → Aug 2015 | — | GeNeuro Innovation SAS | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | temelimab | “Temelimab/GNbAC1 is a humanized immunoglobulin G4 monoclonal antibody antagonist of the human endogenous retrovirus W envelope protein, which is associated with multiple...” PMID 31311668 ↗ Jul 20194“safety of temelimab; a monoclonal antibody neutralizing HERV-W-Env.” PMID 34240656 ↗ Jul 2021 |
| Known as | GNbAC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452996 ↗ |
| Action | Inhibit | “GNbAC1 is an experimental medication, which neutralizes (i.e. inactivates) a protein of MSRV” NCT01639300 ↗1“Syncytin-1 inhibitor” CHEMBL4594547 ↗ |
| Modality | Monoclonal antibody | “GNbAC1 is an immunoglobulin (IgG4) humanised monoclonal antibody” PMID 25392325 ↗ Nov 2014 |
| Route | Intravenous | “Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg” NCT01639300 ↗ |
| Target | ERVW-1 | “Syncytin-1 inhibitor” CHEMBL4594547 ↗ |